Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
| dc.contributor.author | Dias, Matheus Henrique | |
| dc.contributor.author | Friskes, Anoek | |
| dc.contributor.author | Wang, Siying | |
| dc.contributor.author | Fernandes Neto, Joao M. | |
| dc.contributor.author | van Gemert, Frank | |
| dc.contributor.author | Mourragui, Soufiane | |
| dc.contributor.author | Papagianni, Chrysa | |
| dc.contributor.author | Kuiken, Hendrik J. | |
| dc.contributor.author | Mainardi, Sara | |
| dc.contributor.author | Alvarez-Villanueva, Daniel | |
| dc.contributor.author | Lieftink, Cor | |
| dc.contributor.author | Morris, Ben | |
| dc.contributor.author | Dekker, Anna | |
| dc.contributor.author | van Dijk, Emma | |
| dc.contributor.author | Wilms, Lieke H. S. | |
| dc.contributor.author | da Silva, Marcelo S. [UNESP] | |
| dc.contributor.author | Jansen, Robin A. | |
| dc.contributor.author | Mulero-Sánchez, Antonio | |
| dc.contributor.author | Malzer, Elke | |
| dc.contributor.author | Vidal, August | |
| dc.contributor.author | Santos, Cristina | |
| dc.contributor.author | Salazar, Ramón | |
| dc.contributor.author | Wailemann, Rosangela A. M. | |
| dc.contributor.author | Torres, Thompson E. P. | |
| dc.contributor.author | De Conti, Giulia | |
| dc.contributor.author | Raaijmakers, Jonne A. | |
| dc.contributor.author | Snaebjornsson, Petur | |
| dc.contributor.author | Yuan, Shengxian | |
| dc.contributor.author | Qin, Wenxin | |
| dc.contributor.author | Kovach, John S. | |
| dc.contributor.author | Armelin, Hugo A. | |
| dc.contributor.author | Riele, Hein Te | |
| dc.contributor.author | van Oudenaarden, Alexander | |
| dc.contributor.author | Jin, Haojie | |
| dc.contributor.author | Beijersbergen, Roderick L. | |
| dc.contributor.author | Villanueva, Alberto | |
| dc.contributor.author | Medema, Rene H. | |
| dc.contributor.author | Bernards, Rene | |
| dc.contributor.institution | The Netherlands Cancer Institute | |
| dc.contributor.institution | Shanghai Jiao Tong University School of Medicine | |
| dc.contributor.institution | Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center | |
| dc.contributor.institution | L’Hospitalet del Llobregat | |
| dc.contributor.institution | Universidade de São Paulo (USP) | |
| dc.contributor.institution | Universidade Estadual Paulista (UNESP) | |
| dc.contributor.institution | L’Hospitalet de Llobre-gat | |
| dc.contributor.institution | Parc Cientific de Barcelona (PCB) | |
| dc.contributor.institution | CIBERONC | |
| dc.contributor.institution | Instituto Butantan | |
| dc.contributor.institution | Faculty of Medicine | |
| dc.contributor.institution | Eastern Hepatobiliary Surgery Hospital | |
| dc.contributor.institution | Inc. | |
| dc.date.accessioned | 2025-04-29T20:05:46Z | |
| dc.date.issued | 2024-07-01 | |
| dc.description.abstract | Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance. | en |
| dc.description.affiliation | Division of Molecular Carcinogenesis Oncode Institute The Netherlands Cancer Institute | |
| dc.description.affiliation | Division of Cell Biology Oncode Institute The Netherlands Cancer Institute | |
| dc.description.affiliation | State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Renji Hospital Shanghai Jiao Tong University School of Medicine | |
| dc.description.affiliation | Division of Tumor Biology and Immunology The Netherlands Cancer Institute | |
| dc.description.affiliation | Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center | |
| dc.description.affiliation | Division of Molecular Carcinogenesis The Netherlands Cancer Institute | |
| dc.description.affiliation | Chemoresistance and Predictive Factors Group Program Against Cancer Therapeutic Resistance (ProCURE) Catalan Institute of Oncology (ICO) Oncobell Program Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet del Llobregat | |
| dc.description.affiliation | Division of Molecular Carcinogenesis NKI Robotic and Screening Center The Netherlands Cancer Institute | |
| dc.description.affiliation | Department of Biochemistry Institute of Chemistry University of São Paulo, SP | |
| dc.description.affiliation | Department of Chemical and Biological Sciences Institute of Biosciences São Paulo State University (UNESP), SP | |
| dc.description.affiliation | Department of Pathology University Hospital of Bellvitge Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet de Llobre-gat | |
| dc.description.affiliation | Xenopat S.L. Parc Cientific de Barcelona (PCB) | |
| dc.description.affiliation | Department of Medical Oncology Catalan Institute of Oncology (ICO) Oncobell Program Bellvitge Biomedical Research Institute (IDIBELL) CIBERONC | |
| dc.description.affiliation | Center of Toxins Immune-response and Cell Signaling Instituto Butantan | |
| dc.description.affiliation | Department of Clinical and Experimental Oncology Federal University of São Paulo (UNIFESP) | |
| dc.description.affiliation | Department of Pathology The Netherlands Cancer Institute | |
| dc.description.affiliation | University of Iceland Faculty of Medicine | |
| dc.description.affiliation | The Third Department of Hepatic Surgery Eastern Hepatobiliary Surgery Hospital | |
| dc.description.affiliation | Lixte Biotechnology Holdings Inc. | |
| dc.description.affiliationUnesp | Department of Chemical and Biological Sciences Institute of Biosciences São Paulo State University (UNESP), SP | |
| dc.description.sponsorship | European Research Council | |
| dc.description.sponsorship | Generalitat de Catalunya | |
| dc.description.sponsorship | National Natural Science Foundation of China | |
| dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
| dc.description.sponsorship | Instituto de Salud Carlos III | |
| dc.description.sponsorshipId | Generalitat de Catalunya: 2017SGR449 | |
| dc.description.sponsorshipId | Generalitat de Catalunya: 2021 SGR 00184 | |
| dc.description.sponsorshipId | National Natural Science Foundation of China: 22XD1423100 | |
| dc.description.sponsorshipId | FAPESP: 82222047 | |
| dc.description.sponsorshipId | Instituto de Salud Carlos III: PI19-01320 | |
| dc.description.sponsorshipId | Instituto de Salud Carlos III: PI22-00548 | |
| dc.format.extent | 1276-1301 | |
| dc.identifier | http://dx.doi.org/10.1158/2159-8290.CD-23-0216 | |
| dc.identifier.citation | Cancer Discovery, v. 14, n. 7, p. 1276-1301, 2024. | |
| dc.identifier.doi | 10.1158/2159-8290.CD-23-0216 | |
| dc.identifier.issn | 2159-8290 | |
| dc.identifier.issn | 2159-8274 | |
| dc.identifier.scopus | 2-s2.0-85190311153 | |
| dc.identifier.uri | https://hdl.handle.net/11449/306263 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Cancer Discovery | |
| dc.source | Scopus | |
| dc.title | Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy | en |
| dc.type | Artigo | pt |
| dspace.entity.type | Publication |

